The FDA granted fast track designation to brepocitinib for the treatment of nonanterior noninfectious uveitis, according to a press release from Priovant Therapeutics.
In addition, 24-week widefield fluorescein angiography results from the phase 2 NEPTUNE study were presented at the Euretina congress. Regarding the primary efficacy endpoint of treatment failure at 6 months, a 45 mg dose of the tyrosine kinase 2 and Janus kinase 1 inhibitor, a once-daily oral therapy, showed the “numerically greatest efficacy benefit observed to date of any therapy evaluated” for noninfectious